AU2018221076B2 - Substituted imidazo-quinolines as NLRP3 modulators - Google Patents
Substituted imidazo-quinolines as NLRP3 modulators Download PDFInfo
- Publication number
- AU2018221076B2 AU2018221076B2 AU2018221076A AU2018221076A AU2018221076B2 AU 2018221076 B2 AU2018221076 B2 AU 2018221076B2 AU 2018221076 A AU2018221076 A AU 2018221076A AU 2018221076 A AU2018221076 A AU 2018221076A AU 2018221076 B2 AU2018221076 B2 AU 2018221076B2
- Authority
- AU
- Australia
- Prior art keywords
- cancer
- optionally substituted
- independently selected
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 *S(NCc1nc(c(N)nc2c3ccc(-c4n[n]cc4)c2)c3[n]1)(=O)=O Chemical compound *S(NCc1nc(c(N)nc2c3ccc(-c4n[n]cc4)c2)c3[n]1)(=O)=O 0.000 description 1
- AXKDSHWXAVHHCI-UHFFFAOYSA-N CC(NCc1nc(c(N)nc2c3ccc(-c4n[nH]cc4)c2)c3[nH]1)=O Chemical compound CC(NCc1nc(c(N)nc2c3ccc(-c4n[nH]cc4)c2)c3[nH]1)=O AXKDSHWXAVHHCI-UHFFFAOYSA-N 0.000 description 1
- BSDMKWDVYYKUAV-UHFFFAOYSA-N CCC(N(CC)Cc1nc(c(N)nc2c3ccc(-c4n[nH]cc4)c2)c3[nH]1)=O Chemical compound CCC(N(CC)Cc1nc(c(N)nc2c3ccc(-c4n[nH]cc4)c2)c3[nH]1)=O BSDMKWDVYYKUAV-UHFFFAOYSA-N 0.000 description 1
- UHNRLQRZRNKOKU-UHFFFAOYSA-N CCN(Cc1nc(c(N)nc2c3ccc(-c4n[nH]cc4)c2)c3[nH]1)C(C)=O Chemical compound CCN(Cc1nc(c(N)nc2c3ccc(-c4n[nH]cc4)c2)c3[nH]1)C(C)=O UHNRLQRZRNKOKU-UHFFFAOYSA-N 0.000 description 1
- SLBLFZISFRICRM-UHFFFAOYSA-N CCN(Cc1nc(c(N)nc2c3ccc(-c4n[nH]cc4)c2)c3[nH]1)C(C1CC1)=O Chemical compound CCN(Cc1nc(c(N)nc2c3ccc(-c4n[nH]cc4)c2)c3[nH]1)C(C1CC1)=O SLBLFZISFRICRM-UHFFFAOYSA-N 0.000 description 1
- BTEAQDHBXGCZSS-UHFFFAOYSA-N CCN(Cc1nc(c(N)nc2c3ccc(-c4n[nH]cc4)c2)c3[nH]1)C(c1ncc[s]1)=O Chemical compound CCN(Cc1nc(c(N)nc2c3ccc(-c4n[nH]cc4)c2)c3[nH]1)C(c1ncc[s]1)=O BTEAQDHBXGCZSS-UHFFFAOYSA-N 0.000 description 1
- PFOWPCWCGUGDNJ-UHFFFAOYSA-N CN(Cc1nc(c(N)nc2c3ccc(-[n]4nccc4)c2)c3[nH]1)S(C)(=O)=O Chemical compound CN(Cc1nc(c(N)nc2c3ccc(-[n]4nccc4)c2)c3[nH]1)S(C)(=O)=O PFOWPCWCGUGDNJ-UHFFFAOYSA-N 0.000 description 1
- ANRSEYQQKFCFQX-UHFFFAOYSA-N CN(Cc1nc(c(N)nc2c3ccc(-c4n[nH]cc4)c2)c3[nH]1)S(C)(=O)=O Chemical compound CN(Cc1nc(c(N)nc2c3ccc(-c4n[nH]cc4)c2)c3[nH]1)S(C)(=O)=O ANRSEYQQKFCFQX-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Optical Communication System (AREA)
- Adhesives Or Adhesive Processes (AREA)
- Transducers For Ultrasonic Waves (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762460677P | 2017-02-17 | 2017-02-17 | |
| US62/460,677 | 2017-02-17 | ||
| US201762490881P | 2017-04-27 | 2017-04-27 | |
| US62/490,881 | 2017-04-27 | ||
| US201762573991P | 2017-10-18 | 2017-10-18 | |
| US62/573,991 | 2017-10-18 | ||
| PCT/US2018/018484 WO2018152396A1 (en) | 2017-02-17 | 2018-02-16 | Substituted imidazo-quinolines as nlrp3 modulators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2018221076A1 AU2018221076A1 (en) | 2019-10-03 |
| AU2018221076B2 true AU2018221076B2 (en) | 2020-12-24 |
Family
ID=61283434
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2018221076A Active AU2018221076B2 (en) | 2017-02-17 | 2018-02-16 | Substituted imidazo-quinolines as NLRP3 modulators |
Country Status (29)
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106397592A (zh) * | 2015-07-31 | 2017-02-15 | 苏州康宁杰瑞生物科技有限公司 | 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白 |
| CA3029902A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
| JP7159282B2 (ja) | 2017-07-14 | 2022-10-24 | イネイト・テューマー・イミュニティ・インコーポレイテッド | Ｎｌｒｐ３モジュレーター |
| MX2020000911A (es) | 2017-07-24 | 2020-09-10 | Novartis Ag Star | Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp. |
| PE20200758A1 (es) | 2017-08-15 | 2020-07-27 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3 |
| EP3668842A1 (en) | 2017-08-15 | 2020-06-24 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as nlrp3 inhibitors |
| US11926600B2 (en) | 2017-08-15 | 2024-03-12 | Inflazome Limited | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors |
| MD3697789T2 (ro) | 2017-10-18 | 2022-02-28 | Incyte Corp | Derivați imidazol condensați substituiți cu grupări hidroxi terțiare ca inhibitori PI3K-GAMA |
| WO2019092171A1 (en) | 2017-11-09 | 2019-05-16 | Inflazome Limited | Novel sulfonamide carboxamide compounds |
| PE20210050A1 (es) | 2017-11-09 | 2021-01-08 | Inflazome Ltd | Nuevos compuestos de sulfonamida carboxamida |
| EP3759077A1 (en) | 2018-03-02 | 2021-01-06 | Inflazome Limited | Novel compounds |
| KR102711180B1 (ko) | 2018-04-25 | 2024-09-26 | 인네이트 튜머 이뮤니티, 인코포레이티드 | Nlrp3 조정제 |
| US12201627B2 (en) | 2018-08-16 | 2025-01-21 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| US12024513B2 (en) | 2018-08-16 | 2024-07-02 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| JP2021534180A (ja) | 2018-08-16 | 2021-12-09 | イネイト・テューマー・イミュニティ・インコーポレイテッドInnate Tumor Immunity, Inc. | 置換４−アミノ−１Ｈ−イミダゾ［４，５−ｃ］キノリン化合物およびその製造の改良法 |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| CN117088871A (zh) * | 2018-11-30 | 2023-11-21 | 四川科伦博泰生物医药股份有限公司 | 并环化合物、其制备方法及用途 |
| JP7506080B2 (ja) * | 2019-01-14 | 2024-06-25 | イネイト・テューマー・イミュニティ・インコーポレイテッド | Ｎｌｒｐ３モジュレーター |
| EP3911641A1 (en) * | 2019-01-14 | 2021-11-24 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| KR102815870B1 (ko) * | 2019-01-14 | 2025-05-30 | 인네이트 튜머 이뮤니티, 인코포레이티드 | 암의 치료에 사용하기 위한 헤테로시클릭 nlrp3 조정제 |
| CN113195469B (zh) | 2019-02-19 | 2024-05-24 | 四川科伦博泰生物医药股份有限公司 | 含氮并环化合物、其制备方法及用途 |
| EP3937984A1 (en) | 2019-03-15 | 2022-01-19 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| CN116854706B (zh) * | 2019-04-18 | 2025-11-04 | 四川科伦博泰生物医药股份有限公司 | 稠环化合物、其制备方法及用途 |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| US11744874B2 (en) | 2019-12-20 | 2023-09-05 | Nammi Therapeutics, Inc. | Formulated and/or co-formulated liposome compositions containing toll-like receptor (“TLR”) agonist prodrugs useful in the treatment of cancer and methods thereof |
| EP4087842A1 (en) * | 2020-01-10 | 2022-11-16 | Innate Tumor Immunity, Inc. | Nlrp3 modulators |
| KR102409345B1 (ko) * | 2020-09-22 | 2022-06-16 | 가톨릭대학교 산학협력단 | Nlrp3 인플라마좀 억제제 및 이의 용도 |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| CN116874340B (zh) * | 2023-07-10 | 2024-04-05 | 湖北航天化学技术研究所 | 一种苯基炸药类含能共晶化合物及其制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013033345A1 (en) * | 2011-08-30 | 2013-03-07 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US948029A (en) * | 1909-04-23 | 1910-02-01 | James Harvey Leffler | Reclining-chair. |
| CA1271477A (en) | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
| SG46492A1 (en) * | 1991-03-01 | 1998-02-20 | Minnesota Mining & Mfg | 1-Substituted 2-substituted 1H-imidazo [4,5-c] quinolin-4-amines |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US5268376A (en) | 1991-09-04 | 1993-12-07 | Minnesota Mining And Manufacturing Company | 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| JPH1180156A (ja) | 1997-09-04 | 1999-03-26 | Hokuriku Seiyaku Co Ltd | １−（置換アリール）アルキル−１ｈ−イミダゾピリジン−４−アミン誘導体 |
| KR100617337B1 (ko) | 1998-12-23 | 2006-08-31 | 화이자 인크. | Ｃｔｌａ－４에 대한 인간 단일클론 항체 |
| ES2282133T3 (es) | 1999-08-24 | 2007-10-16 | Medarex, Inc. | Anticuerpos frente a la ctla-4 humano y sus usos. |
| GB0023008D0 (en) | 2000-09-20 | 2000-11-01 | Glaxo Group Ltd | Improvements in vaccination |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| AU2003301052A1 (en) | 2002-12-20 | 2004-07-22 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
| EP1592302A4 (en) | 2003-02-13 | 2007-04-25 | 3M Innovative Properties Co | METHODS AND COMPOSITIONS ASSOCIATED WITH IMMUNE RESPONSE MODIFIER COMPOUNDS AND TOLL-LIKE RECEPTOR 8 |
| AU2004266657B2 (en) | 2003-08-14 | 2009-07-02 | 3M Innovative Properties Company | Lipid-modified immune response modifiers |
| US7897597B2 (en) | 2003-08-27 | 2011-03-01 | 3M Innovative Properties Company | Aryloxy and arylalkyleneoxy substituted imidazoquinolines |
| EP1667694B1 (en) | 2003-09-05 | 2010-04-28 | Anadys Pharmaceuticals, Inc. | Tlr7 ligands for the treatment of hepatitis c |
| AR046781A1 (es) | 2003-11-25 | 2005-12-21 | 3M Innovative Properties Co | Derivados de imidazoquinolinas. composiciones farmaceuticas. |
| CN1914203A (zh) | 2003-12-04 | 2007-02-14 | 3M创新有限公司 | 砜取代的咪唑环醚 |
| AU2005228150A1 (en) | 2004-03-24 | 2005-10-13 | 3M Innovative Properties Company | Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| JP2007530579A (ja) | 2004-06-10 | 2007-11-01 | スリーエム イノベイティブ プロパティズ カンパニー | アミド置換イミダゾピリジン、イミダゾキノリン、およびイミダゾナフチリジン |
| WO2005123079A2 (en) * | 2004-06-14 | 2005-12-29 | 3M Innovative Properties Company | Urea substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines |
| WO2005123080A2 (en) | 2004-06-15 | 2005-12-29 | 3M Innovative Properties Company | Nitrogen-containing heterocyclyl substituted imidazoquinolines and imidazonaphthyridines |
| WO2006065280A2 (en) | 2004-06-18 | 2006-06-22 | 3M Innovative Properties Company | Isoxazole, dihydroisoxazole, and oxadiazole substituted imidazo ring compounds and methods |
| US20070259881A1 (en) | 2004-06-18 | 2007-11-08 | Dellaria Joseph F Jr | Substituted Imidazo Ring Systems and Methods |
| EP1797091A2 (en) | 2004-09-14 | 2007-06-20 | Novartis Vaccines and Diagnostics, Inc. | Imidazoquinoline compounds |
| CA2592575A1 (en) | 2004-12-30 | 2006-07-13 | 3M Innovative Properties Company | Immune response modifier formulations and methods |
| JP2008532933A (ja) * | 2005-02-11 | 2008-08-21 | コーリー ファーマシューティカル グループ，インコーポレイテッド | 置換イミダゾキノリン類および置換イミダゾナフチリジン類 |
| US8158794B2 (en) | 2005-02-23 | 2012-04-17 | 3M Innovative Properties Company | Hydroxyalkyl substituted imidazoquinoline compounds and methods |
| CA2598695A1 (en) | 2005-02-23 | 2006-09-21 | Coley Pharmaceutical Group, Inc. | Hydroxyalkyl substituted imidazoquinolines |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| WO2007079086A1 (en) | 2005-12-28 | 2007-07-12 | Coley Pharmaceutical Group, Inc. | Pyrazoloalkyl substituted imidazo ring compounds and methods |
| JP5400763B2 (ja) | 2007-05-08 | 2014-01-29 | アストラゼネカ・アクチエボラーグ | 免疫調節特性を有するイミダゾキノリン類 |
| NZ600758A (en) | 2007-06-18 | 2013-09-27 | Merck Sharp & Dohme | Antibodies to human programmed death receptor pd-1 |
| EP2009002A1 (en) | 2007-06-21 | 2008-12-31 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | New process for the manufacture of 1H-imidazo [4,5-c]-quinoline ring systems |
| TWI605828B (zh) | 2008-12-09 | 2017-11-21 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| WO2010088924A1 (en) | 2009-02-06 | 2010-08-12 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| EP3403672A1 (en) | 2011-04-20 | 2018-11-21 | Medlmmune, LLC | Antibodies and other molecules that bind b7-h1 and pd-1 |
| US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| WO2013173223A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| KR102163408B1 (ko) | 2012-05-31 | 2020-10-08 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Pd-l1에 결합하는 항원 결합 단백질 |
| EP2674170B1 (en) | 2012-06-15 | 2014-11-19 | Invivogen | Novel compositions of TLR7 and/or TLR8 agonists conjugated to lipids |
| US9295732B2 (en) | 2013-02-22 | 2016-03-29 | Invivogen | Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonists |
| KR102243062B1 (ko) | 2013-05-02 | 2021-04-21 | 아납티스바이오, 아이엔씨. | 예정된 사멸-1에 대한 항체 |
| HUE046942T2 (hu) | 2013-05-18 | 2020-04-28 | Aduro Biotech Inc | Készítmények és eljárások "Interferongén-stimulátor"-tól függõ jelátvitel aktiválására |
| WO2014194302A2 (en) | 2013-05-31 | 2014-12-04 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-1 |
| US9227969B2 (en) | 2013-08-14 | 2016-01-05 | Novartis Ag | Compounds and compositions as inhibitors of MEK |
| HUE060420T2 (hu) | 2013-09-13 | 2023-02-28 | Beigene Switzerland Gmbh | Anti-PD1 antitestek, valamint terapeutikumként és diagnosztikumként történõ alkalmazásuk |
| AU2014361473B2 (en) | 2013-12-12 | 2019-09-26 | Jiangsu Hengrui Medicine Co., Ltd. | PD-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| WO2015095780A1 (en) | 2013-12-20 | 2015-06-25 | The University Of Kansas | Toll-like receptor 8 agonists |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| CN105233291A (zh) | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CN112587672A (zh) | 2014-09-01 | 2021-04-02 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| GB201418004D0 (en) | 2014-10-10 | 2014-11-26 | Isis Innovation | Polymer adjuvant |
| CN114702586A (zh) | 2015-03-13 | 2022-07-05 | 西托姆克斯治疗公司 | 抗-pdl1抗体、可活化的抗-pdl1抗体、及其使用方法 |
| RS60792B1 (sr) | 2015-05-29 | 2020-10-30 | Agenus Inc | Anti-ctla-4 antitela i postupci za njihovu primenu |
| WO2017024465A1 (en) | 2015-08-10 | 2017-02-16 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| AR105654A1 (es) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | Anticuerpos pd-l1 (ligando 1 de muerte celular programada) |
| EP3344262A4 (en) | 2015-09-01 | 2019-03-20 | Innate Tumor Immunity, Inc. | IMMUNOCELLS WITH INCREASED IMMUNITY OR RESISTANCE TO AN IMMUNOSUPPRESSIVE CYTOKINE AND USE THEREOF |
| AU2016317915B2 (en) | 2015-09-01 | 2021-02-18 | Agenus Inc. | Anti-PD-1 antibodies and methods of use thereof |
| CN106943597A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| US10730871B2 (en) | 2016-01-28 | 2020-08-04 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
| CN111491362B (zh) | 2016-02-02 | 2023-10-24 | 华为技术有限公司 | 确定发射功率的方法、用户设备和基站 |
| WO2017132827A1 (en) | 2016-02-02 | 2017-08-10 | Innovent Biologics (Suzhou) Co., Ltd. | Pd-1 antibodies |
| US10556903B2 (en) | 2016-04-19 | 2020-02-11 | Innate Tumor Immunity, Inc. | NLRP3 modulators |
| WO2017184735A1 (en) | 2016-04-19 | 2017-10-26 | Ifm Therapeutics, Inc | Nlrp3 modulators |
| TWI674261B (zh) | 2017-02-17 | 2019-10-11 | 美商英能腫瘤免疫股份有限公司 | Nlrp3 調節劑 |
-
2018
- 2018-02-14 TW TW107105417A patent/TWI674261B/zh active
- 2018-02-16 PT PT187076120T patent/PT3510034T/pt unknown
- 2018-02-16 HU HUE18707612A patent/HUE050965T2/hu unknown
- 2018-02-16 ES ES18707612T patent/ES2799900T3/es active Active
- 2018-02-16 LT LTEP18707612.0T patent/LT3510034T/lt unknown
- 2018-02-16 EP EP20169634.1A patent/EP3753938B1/en active Active
- 2018-02-16 SM SM20200375T patent/SMT202000375T1/it unknown
- 2018-02-16 RS RS20200830A patent/RS60548B1/sr unknown
- 2018-02-16 JP JP2019544636A patent/JP7003143B6/ja active Active
- 2018-02-16 SI SI201830085T patent/SI3510034T1/sl unknown
- 2018-02-16 MX MX2019009788A patent/MX390065B/es unknown
- 2018-02-16 AU AU2018221076A patent/AU2018221076B2/en active Active
- 2018-02-16 KR KR1020197026922A patent/KR102329062B1/ko active Active
- 2018-02-16 ME MEP-2020-149A patent/ME03801B/me unknown
- 2018-02-16 MY MYPI2019004704A patent/MY194054A/en unknown
- 2018-02-16 ES ES20169634T patent/ES2978510T3/es active Active
- 2018-02-16 US US15/898,258 patent/US10533005B2/en active Active
- 2018-02-16 PE PE2019001718A patent/PE20191552A1/es unknown
- 2018-02-16 HR HRP20201087TT patent/HRP20201087T1/hr unknown
- 2018-02-16 PL PL18707612T patent/PL3510034T3/pl unknown
- 2018-02-16 SG SG11201907451XA patent/SG11201907451XA/en unknown
- 2018-02-16 CN CN201880012493.7A patent/CN110325534B/zh active Active
- 2018-02-16 WO PCT/US2018/018484 patent/WO2018152396A1/en not_active Ceased
- 2018-02-16 EP EP18707612.0A patent/EP3510034B1/en active Active
- 2018-02-16 DK DK18707612.0T patent/DK3510034T3/da active
- 2018-02-16 CA CA3053949A patent/CA3053949A1/en active Pending
-
2019
- 2019-08-12 IL IL268640A patent/IL268640B/en unknown
- 2019-08-16 CO CONC2019/0008932A patent/CO2019008932A2/es unknown
- 2019-08-16 CL CL2019002324A patent/CL2019002324A1/es unknown
- 2019-09-16 ZA ZA2019/06104A patent/ZA201906104B/en unknown
- 2019-11-25 US US16/693,420 patent/US20200157096A1/en not_active Abandoned
-
2020
- 2020-07-16 CY CY20201100649T patent/CY1123305T1/el unknown
-
2021
- 2021-05-06 US US17/313,319 patent/US11827632B2/en active Active
-
2023
- 2023-10-17 US US18/488,092 patent/US12351580B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013033345A1 (en) * | 2011-08-30 | 2013-03-07 | Regents Of The University Of Minnesota | Immunomodulators and immunomodulator conjugates |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018221076B2 (en) | Substituted imidazo-quinolines as NLRP3 modulators | |
| US11072612B2 (en) | NLRP3 modulators | |
| AU2018301681B2 (en) | NLRP3 modulators | |
| EP3837015A1 (en) | Imidazo[4,5-c]quinoline derived nlrp3-modulators | |
| US12150937B2 (en) | NLRP3 modulators | |
| US12338228B2 (en) | NLRP3 modulators | |
| HK40003517A (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| HK40003517B (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| BR112019016625B1 (pt) | Imidazo-quinolinas substituídas como moduladores de nlrp3, composições farmacêuticas e seus usos para tratar câncer | |
| EP4087842A1 (en) | Nlrp3 modulators | |
| NZ757257B2 (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
| EA037780B1 (ru) | Модуляторы nlrp3 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |